Pressurized intraperitoneal aerosol chemotherapy combined treatment strategies for peritoneal metastases from colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2026.05.010

Abstract

Abstract:

Colorectal cancer peritoneal metastasis (CRCPM) is often accompanied by ascites, abdominal pain and nutritional decline. Measurable lesions on imaging do not always correspond to the patient’s symptoms; therefore, treatment needs to consider both systemic disease and local intraperitoneal problems. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) delivers aerosolized chemotherapeutic agents into the abdominal cavity under pneumoperitoneum, allowing drug deposition on the peritoneal surface and exposure of superficial lesions. Recent studies suggest that PIPAC may be used for symptom control, repeated biopsy-based assessment of peritoneal disease and conversion treatment in selected patients. However, current evidence mainly comes from early-phase trials, single-arm cohorts and retrospective studies, with considerable heterogeneity in patient selection and combined regimens. This review summarizes studies of PIPAC combined with systemic chemotherapy, targeted therapy and CRS+HIPEC, and discusses the potential role of PIPAC in the multidisciplinary treatment of CRCPM.

Key words: Colorectal cancer, Peritoneal metastasis, Pressurized intraperitoneal aerosol chemotherapy

Jinyang Qi, Heyuan Niu, Xiaoping Li, Xingcan Fan, Zijun Liu, Gang Liu. Pressurized intraperitoneal aerosol chemotherapy combined treatment strategies for peritoneal metastases from colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2026, 15(05): 454-459.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2026.05.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2026/V15/I05/454

References 51

[1]	Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries[J]. CA Cancer J Clin, 2026, 76(4): e70090.
[2]	孙可欣, 李荔, 王少明, 等. 2024年中国分地区恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2026, 48(3): 400-412.
[3]	Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3): 263-267.
[4]	Foster JM, Zhang C, Rehman S, et al. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future[J]. CA Cancer J Clin, 2023, 73(1): 49-71.
[5]	Bootsma S, Dings MPG, Kesselaar J, et al. Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases[J]. Cell Rep Med, 2024, 5(5): 101523.
[6]	Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy[J]. Cancer Commun (Lond), 2022, 42(8): 689-715.
[7]	Rietveld PCS, Guchelaar NaD, Sassen SDT, et al. A clinical pharmacological perspective on intraperitoneal chemotherapy[J]. Drugs, 2025, 85(7): 931-943.
[8]	Pan S, Yuan H, Zhai Q, et al. The journey of nanoparticles in the abdominal cavity: exploring their in vivo fate and impact factors[J]. J Control Release, 2024, 376: 266-285.
[9]	Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7): e368-e377.
[10]	Reymond MA, Holthaus K, Wiebke S. Giving patients more good days: the promise of pessurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis[J]. Eur J Surg Oncol, 2026, 52(1): 111206.
[11]	Guchelaar NaD, Noordman BJ, Koolen SLW, et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies[J]. Drugs, 2023, 83(2): 159-180.
[12]	Robella M, Vitturini M, Di Giorgio A, et al. Advances in bidirectional therapy for peritoneal metastases: a systematic review of pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with systemic chemotherapy[J]. Cancers (Basel), 2025, 17(15): 2580.
[13]	Lurvink RJ, Rovers KP, Nienhuijs SW, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review[J]. J Gastrointest Oncol, 2021, 12(Suppl. 1): s242-s258.
[14]	Sleiman MJ, Jelip A, Buchs N, et al. Pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a systematic review of the evidence[J]. Cancers (Basel), 2024, 16(21): 3661.
[15]	徐璐, 孙婧. 结直肠癌伴腹膜转移治疗的研究进展[J]. 临床肿瘤学杂志, 2023, 28(1): 84-89.
[16]	黄莹莹, 赵赟博. 腹膜转移癌内科治疗新进展[J]. 中国肿瘤临床, 2020, 47(3): 123-127.
[17]	Baggaley AE, Lafaurie G, Tate SJ, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework[J]. Br J Surg, 2022, 110(1): 10-18.
[18]	Perelló-Trias MT, Serrano-Muñoz AJ, Rodríguez-Fernández A, et al. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: bridging the gap between research and clinical implementation[J]. J Control Release, 2024, 373: 70-92.
[19]	Raoof M, Whelan RL, Sullivan KM, et al. Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA[J]. Ann Surg Oncol, 2023, 30(12): 7814-7824.
[20]	Kyle P, Perry K, Moutadjer A, et al. UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228)[J]. Pleura Peritoneum, 2023, 8(4): 157-165.
[21]	De Bree E, Michelakis D, Stamatiou D, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy[J]. Pleura Peritoneum, 2017, 2(2): 47-62.
[22]	So JBY. Bi-directional chemotherapy for peritoneal metastases[J]. Br J Surg, 2023, 110(6): 627-628.
[23]	Graversen M, Detlefsen S, Ainsworth AP, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study[J]. Ann Surg Oncol, 2023, 30(5): 2634-2644.
[24]	Marrelli D, Carbone L, Fusario D, et al. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) for peritoneal malignancies with palliative and bidirectional intent[J]. Cancers (Basel), 2025, 17(12): 1938.
[25]	Catania G, Zilio S, Bakrin N, et al. Immunomodulatory intraperitoneal chemotherapy with DACHPt-loaded biomaterial nanoparticles in colorectal carcinomatosis[J]. Pharmacol Res, 2025, 222: 108035.
[26]	Kovalyk X, Saniternik S, Hamacher LM, et al. Gelatin and collagen-mimetic nanoparticles for intraperitoneal cisplatin delivery: from synthesis to in-vivo SPECT imaging of biodistribution[J]. Biomater Adv, 2026, 180: 214601.
[27]	Constantinides A, Lansu N, Mosen P, et al. Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade[J]. Transl Oncol, 2025, 59: 102464.
[28]	Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. a single center comparative study[J]. Eur J Surg Oncol, 2021, 47(1): 139-142.
[29]	Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone[J]. Br J Cancer, 2014, 111(8): 1500-1508.
[30]	Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin[J]. J Clin Oncol, 2009, 27(5): 681-685.
[31]	Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study[J]. Cancer, 2000, 88(2): 358-363.
[32]	Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. Lancet Oncol, 2015, 16(13): 1306-1315.
[33]	Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 256-266.
[34]	Lundbech M, Krag AE, Iversen LH, et al. Elevated thrombin generation and venous thromboembolism incidence in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy compared with minimally invasive rectal surgery[J]. Thromb Haemost, 2025, 125(5): 460-469.
[35]	Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study[J]. J Clin Oncol, 2010, 28(1): 63-68.
[36]	Aulicino M, Santullo F, D’annibale G, et al. Efficacy and insights from an extensive series of cytoreductive surgery for peritoneal neoplasms: a high-volume single-center experience[J]. Cancers (Basel), 2024, 16(24): 4229.
[37]	Girshally R, Demtröder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1): 253.
[38]	Alyami M, Mercier F, Siebert M, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Eur J Surg Oncol, 2021, 47(1): 128-133.
[39]	Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study[J]. J Clin Oncol, 2004, 22(16): 3284-3292.
[40]	Tabchouri N, Buggisch J, Demtröder CR, et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases[J]. Ann Surg Oncol, 2021, 28(9): 5275-5286.
[41]	Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
[42]	Jørgensen MS, Ainsworth AP, Fristrup CW, et al. Prognostic value of baseline peritoneal fluid cytology in 224 patients with unresectable peritoneal metastasis treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC)[J]. Hum Pathol, 2025, 168: 106017.
[43]	Roensholdt S, Graversen M, Detlefsen S, et al. The role of inflammatory biomarkers in PIPAC: predicting survival and treatment completion in patients with peritoneal metastasis[J]. J Cancer, 2026, 17(1): 10-20.
[44]	Van De Vlasakker VCJ, Rauwerdink P, Rovers KPB, et al. Patient-reported outcomes during first-line palliative systemic therapy alternated with pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-Ⅱ)[J]. Surg Endosc, 2024, 38(11): 6566-6576.
[45]	Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC)[J]. Eur J Surg Oncol, 2015, 41(10): 1379-1385.
[46]	Kryh-Jensen CG, Fristrup CW, Ainsworth AP, et al. What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC)[J]. Pleura Peritoneum, 2023, 8(4): 147-155.
[47]	Lurvink RJ, Rovers KP, Wassenaar ECE, et al. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)[J]. Surg Endosc, 2022, 36(6): 4486-4498.
[48]	Van De Vlasakker VCJ, Lurvink RJ, Wassenaar EC, et al. Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery[J]. Sci Rep, 2023, 13(1): 20458.
[49]	《加压腹腔气溶胶化疗技术及操作规范与职业防护》编审委员会. 加压腹腔气溶胶化疗技术及操作规范与职业防护建议(2026版)[J]. 中华胃肠外科杂志, 2026, 29(4): 393-408.
[50]	刘磊, 胡烨婷, 孔祥兴, 等. 结直肠癌腹膜转移转化治疗策略与手术时机选择[J]. 中华胃肠外科杂志, 2026, 29(5): 636-647.
[51]	Tozzi F, Rashidian N, Ceelen W, et al. Standardizing eligibility and patient selection for pressurized intraperitoneal aerosol chemotherapy: a Delphi consensus statement[J]. Eur J Surg Oncol, 2024, 50(6): 108346.

Please choose a citation manager

Content to export